Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study

Sunday, November 10, 17:00–17:15. Georgia World Congress Center, Atlanta, USA

Presenting author: Stanley B Cohen, USA

What our Editorial Board said:

This is the first phase II trial of a Bruton’s tyrosine kinase (BTK) inhibitor in patients with rheumatoid arthritis (RA) identified as a population with existing unmet medical need.  This reasonably sized trial should provide useful information regarding whether or not this anticipated class of biologics demonstrates significant clinical efficacy in a challenging subset of previously treated patients with RA.

– Marc D Cohen, USA